Verification: a0d6e82a7952e405

LFHCK a.k.a LiFeHaCK

Lawsuit Accuses Drug Giant of Concealing Zantac’s Cancer Link

Published by

TEDDIE

on

The British pharmaceutical company GlaxoSmithKline (GSK) has faced accusations of concealing a study allegedly demonstrating a connection between its drug Zantac and certain risks.
cancer
, a fresh lawsuit has alleged.

A pension fund has initiated a class-action lawsuit against the company in the United States, accusing GlaxoSmithKline (GSK) and three top officials, including CEO Emma Walmsley, of deceiving shareholders by stating they were unaware of any link between their heartburn drug Zantac and cancer risks.

Zantac became available for purchase in the United Kingdom in 1981, and by 1988, it had become the globe’s quickest-selling medication.

However, in 2019, GSK removed it from the UK and US markets due to concerns that ranitidine, an ingredient in the product, formed a potentially cancer-causing chemical when mixed with nitrates, commonly present in various foods.

In the United States, tens of thousands of individuals pursued compensation. At the time, GSK stated that the prevailing scientific opinion was that there was ‘no consistent or reliable evidence suggesting that ranitidine raises the risk of… cancer’.

In October, GSK stated that they had expended $2.2 billion resolving 93 percent of the cases without acknowledging fault.

However, in a legal case submitted to the US district court in
Pennsylvania
The Roofers Local No. 149 Pension Fund claimed that GSK knew about the connection between Zantac and cancer for approximately 40 years before the drug was withdrawn.




Legal papers assert that in 1982, Richard Tanner, who was a researcher at Glaxo—a company that later became part of GSK—discovered that when ranitidine came into contact with nitrites, it generated approximately 232,000 nanograms of NDMA, which is a cancer-causing substance.

Subsequently, the U.S. pharmaceutical regulatory body declared that a drug should contain no more than 96 nanograms as permissible.

The allegation asserts that Glaxo and GSK concealed the report, resulting in ‘financial harm’ for investors as GSK’s stock value was impacted by the lawsuits.

GSK stated: “We’re currently examining this legal case.”

Since 2019, after evaluating 16 epidemiological studies examining human data related to the consumption of ranitidine, the prevailing opinion among scientists is that there is no consistent or dependable evidence suggesting an increased risk of any form of cancer associated with using ranitidine.

‘After the initial Zantac personal injury lawsuit was filed in 2019, we have reported the associated legal actions concerning Zantac as a possible risk factor and maintained regular communication with our shareholders.’

Read more

Discover more from LFHCK a.k.a LiFeHaCK

Subscribe to get the latest posts sent to your email.

Leave a Reply

Previous Post
Next Post

Recent posts

Quote of the week

"People ask me what I do in the winter when there's no baseball. I'll tell you what I do. I stare out the window and wait for spring."

~ Rogers Hornsby

LFHCK a.k.a LiFeHaCK

About

Lifehack Your Life is a simple content personal blogger from everywhere.

Topics

Made with 🩷 in Yogyakarta Indonesia

Share This

Share This

Share this post with your friends!

Discover more from LFHCK a.k.a LiFeHaCK

Subscribe now to keep reading and get access to the full archive.

Continue reading